Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 4, 2010, Pages 484-490

  Chiappori, Alberto A ^a   Zheng, Zhong ^a   Chen, Tingan ^a   Rawal, Bhupendra ^a   Schell, Michael J ^a   Mullaney, Brian P ^b   Bepler, Gerold ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Chemosensitivity; Immunofluorescence based automated quantitative analysis (AQUA); Predictive biomarkers; Small cell lung cancer (SCLC)

Indexed keywords

BIOLOGICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING); EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FOLYLPOLYGLUTAMATE SYNTHASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; RIBONUCLEOTIDE REDUCTASE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONFOCAL MICROSCOPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TREATMENT RESPONSE;

EID: 77951009287     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ccb27b     Document Type: Article

References (50)

1. Janne PA, Freidlin B, Saxman S, et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002;95:1528-1538.
2. Simon GR, Wagner H. Small cell lung cancer. Chest 2003;123:259S- 271S. (Pubitemid 36138804)
3. Davies AM, Lara PN, Lau DH, et al. Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am 2004;18:373-385. (Pubitemid 38496473)
4. Ettinger DS. New drugs for chemotherapy-naive patients with extensivedisease small cell lung cancer. Semin Oncol 2001;28:27-29. (Pubitemid 32730375)
5. Ettinger DS. Single-agent paclitaxel in the treatment of small cell lung cancer. Semin Oncol 1996;23:16-17. (Pubitemid 27068980)
6. Hesketh PJ, Crowley JJ, Burris HA III, et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am 1999;5:237-241. (Pubitemid 29528752)
7. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996;14:2345-2352. (Pubitemid 26264887)
8. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225-1229.
9. Socinski MA, Weissman C, Hart LL, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol 2006;24:4840-4847. (Pubitemid 46630910)
10. Chiappori AA, Rocha-Lima CM. New agents in the treatment of smallcell lung cancer: focus on gemcitabine. Clin Lung Cancer 2003;4 (suppl 2):S56-S63.
11. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043. (Pubitemid 46622112)
12. Lara PN Jr, Gandara DR, Natale RB. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensivestage small-cell lung cancer. Clin Lung Cancer 2006;7:353-356. (Pubitemid 43950985)
13. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy- naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009;27:4787-4792.
14. Heigener DF, Freitag L, Eschbach C, et al. Topotecan/cisplatin compared to cisplatin/etoposide for patients with extensive stage small cell lung cancer. Final results of a phase III randomised study. J Clin Oncol 2008;26 (15 suppl):400s (abstract 7513).
15. Bepler G. Using translational research to tailor the use of chemotherapy in the treatment of NSCLC. Lung Cancer 2005;50 (suppl 1):S13-S14. (Pubitemid 41618292)
16. Bepler G. Pharmacogenomics: a reality or still a promise? Lung Cancer 2006;54 (suppl 2):S3-S7. (Pubitemid 44692849)
17. Plunkett W, Huang P, Searcy CE, et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996;23:3-15. (Pubitemid 26362189)
18. Larsen AK, Skladanowski A, Bojanowski K. The roles of DNA topoisomerase II during the cell cycle. Prog Cell Cycle Res 1996;2:229-239.
19. Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000;20:645-652. (Pubitemid 30240614)
20. Rose MG, Farrell MP, Schmitz JC. Thymidylate synthase: a critical target for cancer chemotherapy. Clin Colorectal Cancer 2002;1:220-229. (Pubitemid 34269382)
21. Uesaka T, Shono T, Kuga D, et al. Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. J Neurooncol 2007;84:119-129. (Pubitemid 47202120)
22. Tinari N, Lattanzio R, Natoli C, et al. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res 2006;12:1501-1506.
23. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991. (Pubitemid 44343542)
24. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-983. (Pubitemid 40775532)
25. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006;24:4731-4737. (Pubitemid 46646245)
26. Bepler G, Sommers KE, Cantor A, et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008;3:1112-1118.
27. Liu JM, Wang LS, Huang MH, et al. Topoisomerase 2alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia. Cancer 2007;109:502-509.
28. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005;11:6100-6102. (Pubitemid 41262934)
29. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-2291. (Pubitemid 34753602)
30. Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004;64: 3761-3766. (Pubitemid 38697284)
31. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004;10: 1318-1325. (Pubitemid 38365223)
32. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004;10:4215s- 4219s. (Pubitemid 38812449)
33. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007;25:2741-2746. (Pubitemid 47123182)
34. Rosell R, Cobo M, Isla D, et al. ERCC1 mRNA-based randomized Phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem)in stage IV non-small clell lung cancer (NSCLC) patients (p). Proc ASCO 2005;23:621s.
35. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-1327. (Pubitemid 35373567)
36. Shi SR, Cote RJ, Taylor CR. Antigen retrieval immunohistochemistry: past, present, and future. J Histochem Cytochem 1997;45:327-343. (Pubitemid 27120589)
37. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-808. (Pubitemid 46294612)
38. Dotzlaf J, Carpenter J, Luo S, et al. Derivation and characterization of monoclonal antibodies against human folypolyglutamate synthetase. Hybridoma (Larchmt) 2007;26:155-161. (Pubitemid 47052627)
39. Dotzlaf J, Carpenter J, Luo S, et al. Derivation and characterization of a monoclonal antibody against human glycinamide ribonucleotide formyltransferase. Hybridoma (Larchmt) 2006;25:139-144. (Pubitemid 43967699)
40. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-878.
41. Gazdar AF, Steinberg SM, Russell EK, et al. Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst 1990;82:117-124.
42. Cortazar P, Gazdar AF, Woods E, et al. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res 1997;3:741-747. (Pubitemid 27244341)
43. Weisenthal LM, Marsden JA, Dill PL, et al. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 1983;43:749-757.
44. Cortazar P, Johnson BE. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 1999;17:1625-1631. (Pubitemid 29220873)
45. Bubendorf L, Nocito A, Moch H, et al. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 2001;195:72-79.
46. McCabe A, Dolled-Filhart M, Camp RL, et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808 -1815. (Pubitemid 43033901)
47. Zheng Z, Li X, Schell MJ, et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008;112:2765-2773. (Pubitemid 351969222)
48. Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
49. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795. (Pubitemid 33115977)
50. Ceppi P, Longo M, Volante M, et al. Excision repair cross complementing- 1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. J Thorac Oncol 2008;3:583-589. (Pubitemid 351787300)